lysyl-aspartyl-glutamyl-leucine has been researched along with Breast Cancer in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (50.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Batra, SK; Bigner, DD; Lorimer, IA; Pastan, I; Wikstrand, CJ | 1 |
Abad, JL; Bernad, A; Gómez-Moutón, C; González, MA; Lacalle, RA; Mañes, S; Martínez-A, C; Mira, E | 1 |
2 other study(ies) available for lysyl-aspartyl-glutamyl-leucine and Breast Cancer
Article | Year |
---|---|
Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors.
Topics: 3T3 Cells; Animals; Antibodies, Monoclonal; Breast Neoplasms; Cell Survival; Drug Design; ErbB Receptors; Female; Glioma; Humans; Immunotoxins; Lung Neoplasms; Mice; Mutagenesis, Site-Directed; Oligopeptides; Protein Sorting Signals; Recombinant Proteins; Sequence Deletion; Transfection | 1995 |
A role for chemokine receptor transactivation in growth factor signaling.
Topics: Breast Neoplasms; Cell Polarity; Chemokine CCL5; Chemotaxis; GTP-Binding Protein alpha Subunits, Gi-Go; Humans; Insulin-Like Growth Factor I; Ligands; Mutation; Neoplasm Invasiveness; Oligopeptides; Phosphorylation; Protein Sorting Signals; Receptors, CCR5; RNA, Messenger; Signal Transduction; Transcriptional Activation; Tumor Cells, Cultured | 2001 |